<DOC>
	<DOC>NCT00725543</DOC>
	<brief_summary>This is a prospective, open-label, 1-arm, multicenter observational study to determine the dose and time span of Remicade between infusions for ankylosing spondylitis (AS).</brief_summary>
	<brief_title>Investigation of 9 Consecutive Remicade Infusions in Ankylosing Spondylitis in Austria (Study P04044)(COMPLETED)</brief_title>
	<detailed_description>This study population was chosen from a non-probability sample.</detailed_description>
	<mesh_term>Spondylitis</mesh_term>
	<mesh_term>Spondylitis, Ankylosing</mesh_term>
	<mesh_term>Infliximab</mesh_term>
	<criteria>Subjects with ankylosing spondylitis with severe axial symptoms and elevated serological markers of inflammatory activity. Subjects with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections. Subjects with moderate or severe heart failure (New York Heart Association (NYHA) class III/IV). Subjects with a history of hypersensitivity to Remicade or to other murine proteins, or to any of the excipients.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>